Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 612

[413] Natarajan A, DeNardo SJ. PEGylation of antibody fragments to improve pharmacody-
namics and pharmacokinetics. In: Kontermann R, Dubel S, editors. Antibody engineer-
ing. 2nd ed., vol. 2 Berlin/Heidelberg: Springer; 2010. p. 191-205.
[414] Hamidi M, Rafiei P, Azadi A. Designing PEGylated therapeutic molecules: advantages
in ADMET properties. Expert Opin Drug Discovery 2008;3:1293-307.
[415] Jen A, Merkle HP. Diamonds in the rough: protein crystals from a formulation perspec-
tive. Pharm Res 2001;18:1483-8.
[416] Ayala M, Horjales E, Pickard MA, Vazquez-Duhalt R. Cross-linked crystals of chloro-
peroxidase. Biochem Biophys Res Commun 2002;295:828-31.
[417] Basu SK, Govardam CP, Jung CW, Margolin AL. Protein crystals for the delivery of
biopharmaceuticals. Expert Opin Biol Ther 2004;4:301-17.
[418] Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL. Injectable controlled release
formulations incorporating protein crystals. J Control Release 2004;96:149-58.
[419] Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci
1999;88:489-500.
[420] Heras B, Martin JL. Post-crystallization treatments for improving diffraction quality of
protein crystals. Acta crystallographica section D. Int Union Crystallo 2005;61:1173-80.
[421] Beals JM, Shanafelt AB. Enhancing exposure of protein therapeutics. Drug Discov
Today Technol 2006;3:87-94.
[422] Bromerg L, Rashba-Step J, Scott T. Insulin particles formation in supersaturated aque-
ous solution of poly (ethylene glycol). Biophys J 2005;89:3424-33.
[423] Altus ® publishes results of pioneering technology to develop alternative delivery meth-
ods for monoclonal antibody therapeutics using crystalline formulations. http:// ir.altus.
com/releasedetail.cfm?ReleaseID182584. Accessed May 2010.
[424] Govardhan C, Khalaf N, Jung CW, Simeone B, Higbie A, Qu S, et al. Novel long-acting
crystal formulation of human growth hormone. Pharm Res 2005;22:1461-70.
[425] Doer A. Widening the protein crystallization bottleneck. Nat Methods 2006;3:961.
[426] Emergence of prefilled syringes. 2007. Express Pharma . June. (p. 16-30). http:// www.
expresspharmaonline.com/20070630/cphlchina07.shtml . Accessed May 2010.
[427] Prefilled syringes: device suppliers meeting pharmaceutical standards. http:// www.
ondrugdelivery.com/publications/Prefilled_syringes_%2007.pdf . Accessed May 2010.
[428] Harrison B, Rios M. Big shot: development in prefilled syringes. Pharm Technol
2007;30:50-60.
[429] Overcashier DE, Chan EK, Hsu CC. Technical considerations in the development of
prefilled syringes for protein products. Am Pharm Rev 2006;9:77-83.
[430] Machak DR (2008). Pre-filled syringes (PFS)—an introduction to breakage and defects.
Am Pharm Rev Sept./Oct. Article serial no. 3663. http:// americanpharmaceuticalreview.
com/ViewArticle.aspx?ContentID3663. Accessed May 2010.
[431] Success with Pegasys right from the start. http:// www.pegasys.com/hcp/success.aspx .
Accessed May 2010.
[432] European prefilled syringes markets. 2005. http:// www.frost.com/prod/servlet/report-
brochure.pag?id B773-01-00-00-00. Accessed May 2010.
[433] Sinha VJ, Trehan A, Tiwari P. Needle-free injection technology. Express HealthCare
Management July 2005(1-15).
[434] Chase CCL, Daniels CS, Garcia R. Needle-free injection technology in swine: Progress
toward vaccine efficacy and pork quality. J Swine Health Prod. 2008;16(5):254-261.
[435] Pass F, Hayes J. Needle-free drug delivery. In: Rathbone MJ, Hadgraft J, Roberts MS,
editors. Modified-release drug delivery technology, vol. 126. New York, NY: Marcel
Dekker; 2003. p. 599-606.